Menu

ISTOCK, SELIMAKSAN

Mitochondrial Infusions Given to Babies with Heart Damage

Among 11 infants treated to date, most survived and their heart function improved.

Jul 10, 2018
Kerry Grens

Eleven babies have been given an experimental treatment to repair damaged heart tissue: 1 billion of their own mitochondria infused into the impaired cardiac muscle. So far, The New York Times reports, eight babies have survived and their hearts are working better; in comparison, 65 percent of similar babies who don’t receive the treatment die and none experience an improvement in their cardiac function.

“They gave her a fighting chance,” Kate Bowen, the mother of one of the babies who was treated, tells The Times. Her daughter Georgia went into cardiac arrest after birth and was kept alive with a machine that operated her lungs and heart. She can now breathe on her own, although her heart has not fully recovered.

Mitochondrial transplants come from the patients’ own healthy cells in another part of the body. They are then isolated and delivered to the heart. 

Doctors who developed the technique tried it out on the first baby in 2015. The newborn had suffered heart damage during a surgery to repair a congenital defect in the heart. Within two days, The Times reports, the baby’s heart was beating normally. “It was amazing,” Sitaram Emani, the pediatric surgeon at Boston Children’s Hospital who performed the operation, tells the newspaper.

The procedure is “a really intriguing option” to test out in adults, Peter Smith, chief of cardiothoracic surgery at Duke University, tells The Times. Experiments in adults are being planned.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.